Public research evidence case
CJC-1295 With DAC: Randomized Human Pharmacology and the Albumin-Binding Boundary
A close reading of the two randomized ascending-dose studies in healthy adults, focusing on GH and IGF-I time courses, estimated half-life and why the findings do not apply to CJC-1295 without DAC.
- Study design
- Two randomized, placebo-controlled, double-blind ascending-dose trials
- Sample
- Healthy adults aged 21–61; single- and multiple-dose cohorts
- Duration
- 28 and 49 days
- Model / population
- Healthy adult human pharmacokinetic/pharmacodynamic study
Structured evidence record
What the source actually reports
Primary question and endpoints
Peak concentrations and area under the curve for GH and IGF-I, together with standard pharmacokinetic parameters for CJC-1295.
Reported result
After one dose, mean plasma GH increased 2- to 10-fold for at least six days and mean IGF-I increased 1.5- to 3-fold for 9–11 days. Estimated CJC-1295 half-life was 5.8–8.1 days. The authors reported no serious adverse reactions in these short studies.
Limitations
The studies were short, dose-escalating pharmacology trials in healthy volunteers, not trials of clinical benefit. The abstract does not support disease-treatment, body-composition or long-term safety claims, and the later development history is not resolved by this paper.
Material and interpretation boundary
The published long time course depends on the Drug Affinity Complex albumin-binding design. CJC-1295 without DAC is a materially different identity; the 5.8–8.1-day estimate and prolonged hormone profile must not be assigned to the no-DAC form.
The identity issue comes before the result
The cited compound was engineered as a long-acting GHRH analog that binds endogenous albumin. That design feature is central to the pharmacokinetic question. Search pages frequently collapse “with DAC” and “without DAC” into one name, but doing so changes the molecular identity and invalidates a direct transfer of the reported half-life.
What the trials measured
The two trials were randomized, placebo-controlled, double-blind and dose ascending. Their main outcomes were circulating GH and IGF-I exposure plus pharmacokinetic parameters. Those are pharmacology endpoints. They are not direct measures of improved health, body composition or performance.
The reported time course
The authors reported sustained, dose-dependent GH and IGF-I increases and an estimated half-life measured in days. A companion study reported that pulsatile GH secretion remained observable under the prolonged stimulus. These records support a mechanistic and time-course discussion for the DAC form only.
What the study does not establish
Short early-phase hormone and exposure data do not establish therapeutic efficacy, long-term safety or the quality of a commercial lot. A current lot requires its own identity, assay and release documentation; literature cannot substitute for those controls.
Primary records
Sources and traceability
- Prolonged stimulation of GH and IGF-I secretion by CJC-1295Open source ↗
Teichman SL, et al. J Clin Endocrinol Metab. 2006. PMID 16352683.
- Pulsatile GH secretion persists during CJC-1295 stimulationOpen source ↗
Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006. PMID 17018654.
This page is an editorial reading of a public source, not a customer testimonial, medical advice or a claim that a catalog material reproduces the cited intervention.